Stereotactic Radiosurgery for Multiple Brain Metastases

Johannes Kraft*, Jaap Zindler, Giuseppe Minniti, Matthias Guckenberger, Nicolaus Andratschke

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

30 Citations (Web of Science)

Abstract

Purpose of review To give an overview on the current evidence for stereotactic radiosurgery of brain metastases with a special focus on multiple brain metastases.

Recent findings While the use of stereotactic radiosurgery in patients with limited brain metastases has been clearly defined, its role in patients with multiple lesions (> 4) is still a matter of controversy. Whole-brain radiation therapy (WBRT) has been the standard treatment approach for patients with multiple brain lesions and is still the most commonly used treatment approach worldwide. Although distant brain failure is improved by WBRT, the overall survival is not readily impacted. As WBRT is associated with significant neurocognitive decline compared to stereotactic radiosurgery (SRS), SRS has been explored and increasingly utilized for selected patients with multiple brain metastases. Recent clinical data indicated the feasibility of stereotactic radiosurgery to multiple brain metastases with a similar survival in patients with more than 4 brain metastases versus patients with a maximum of 4 brain metastases. Also, neurocognitive function and quality of life was maintained after stereotactic radiosurgery which is essential in a palliative setting.

Summary The application of stereotactic radiosurgery with Gamma Knife, Cyberknife, or LINAC-based equipment has emerged as an effective and widely available treatment option for patients with limited brain metastases. Although not formally proven in prospective studies, SRS may also be considered as a safe and effective treatment option in selected patients with multiple brain metastases. Especially in patients with a favorable prognosis, survival over several years is observed also in the setting of multiple BM. For these patients, avoidance of the neurocognitive damage of WBRT is desirable, and SRS is often a more appropriate treatment in the current multimodality treatment of BM in which systemic treatment is often the cornerstone of the treatment. For patients with an intermediate (3-12 months) and poor prognosis (

Original languageEnglish
Article number6
Number of pages15
JournalCurrent Treatment Options in Neurology
Volume21
Issue number2
DOIs
Publication statusPublished - Jan 2019

Keywords

  • Brain metastases
  • Multiple brain metastases
  • Stereotactic radiosurgery
  • CELL LUNG-CANCER
  • GAMMA-KNIFE SURGERY
  • GRADED PROGNOSTIC ASSESSMENT
  • RECURSIVE PARTITIONING ANALYSIS
  • RADIATION-THERAPY
  • OPEN-LABEL
  • NON-INFERIORITY
  • RANDOMIZED-TRIAL
  • SINGLE-ARM
  • RADIOTHERAPY

Cite this